STAAR Surgical (STAA) Downgraded by BidaskClub

BidaskClub cut shares of STAAR Surgical (NASDAQ:STAA) from a sell rating to a strong sell rating in a research note issued to investors on Saturday.

Several other research firms have also issued reports on STAA. Benchmark reissued a buy rating and set a $21.00 target price on shares of STAAR Surgical in a report on Monday, November 20th. Canaccord Genuity increased their target price on STAAR Surgical from $17.50 to $20.00 and gave the stock a buy rating in a report on Friday, November 17th. Finally, Zacks Investment Research lowered STAAR Surgical from a buy rating to a hold rating in a report on Wednesday, October 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $17.67.

STAAR Surgical (STAA) traded up $0.35 on Friday, hitting $16.15. The stock had a trading volume of 123,900 shares, compared to its average volume of 86,920. The firm has a market cap of $654.51, a price-to-earnings ratio of -323.00 and a beta of 1.19. STAAR Surgical has a 12 month low of $8.95 and a 12 month high of $17.60. The company has a current ratio of 2.24, a quick ratio of 1.72 and a debt-to-equity ratio of 0.02.

In other news, VP Keith Holliday sold 6,000 shares of the stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total transaction of $99,900.00. Following the sale, the vice president now directly owns 45,969 shares of the company’s stock, valued at approximately $765,383.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.40% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantum Capital Management acquired a new stake in shares of STAAR Surgical during the 3rd quarter worth $710,000. Vanguard Group Inc. boosted its stake in STAAR Surgical by 0.6% in the second quarter. Vanguard Group Inc. now owns 1,280,775 shares of the medical instruments supplier’s stock valued at $13,832,000 after buying an additional 7,803 shares in the last quarter. Menta Capital LLC boosted its stake in STAAR Surgical by 11.3% in the second quarter. Menta Capital LLC now owns 206,321 shares of the medical instruments supplier’s stock valued at $2,228,000 after buying an additional 20,913 shares in the last quarter. Teachers Advisors LLC boosted its stake in STAAR Surgical by 13.5% in the second quarter. Teachers Advisors LLC now owns 84,044 shares of the medical instruments supplier’s stock valued at $908,000 after buying an additional 10,000 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in STAAR Surgical by 26.2% in the second quarter. New York State Common Retirement Fund now owns 44,800 shares of the medical instruments supplier’s stock valued at $484,000 after buying an additional 9,299 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

WARNING: “STAAR Surgical (STAA) Downgraded by BidaskClub” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/08/staar-surgical-staa-downgraded-by-bidaskclub.html.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit